New restrictions on access to a drug used in the most common form of abortion would be imposed under a federal appeals court ruling issued Wednesday, but the Supreme Court will have the final say. The ruling by three judges on the 5th US Circuit Court of Appeals in New Orleans overturned part of a lower court ruling that revoked the FDA's approval—more than two decades ago—of mifepristone. But it left intact part of the ruling that would end the availability of the drug by mail and require that the drug be administered in the presence of a physician.
Those restrictions won't take effect, at least right away, because the Supreme Court previously intervened to keep the drug available during the legal fight. At issue is a Texas-based federal judge's April ruling revoking the drug's approval. There is no precedent for a US court overturning the approval of a drug that the FDA has deemed safe and effective, the AP reports. While new drug safety issues often emerge after FDA approval, the agency is required to monitor medicines on the market, evaluate emerging issues, and take action to protect US patients. Congress delegated that responsibility to the FDA—not the courts—more than a century ago.
But during a May 17 hearing, the 5th Circuit panel—Judges Jennifer Walker Elrod, James Ho, and Cory Wilson—pushed back frequently against assertions that US District Judge Matthew Kacsmaryk's April 7 ruling was unprecedented and unwarranted. Kacsmaryk, Ho, and Wilson are all appointees of former President Trump. Elrod was appointed to the 5th Circuit by former President George W. Bush. All of the judges have a history of supporting abortion restrictions. The Texas lawsuit was filed by the Alliance Defending Freedom, a conservative Christian legal group that was also involved in the Mississippi case that led to the June 2022 Supreme Court ruling overturning Roe v. Wade and the nationwide right to abortion.
(More
mifepristone stories.)
,
uBlock 
,
and
Ghostery 
)
